HSD17B13

• Haploinsufficiency score: Haploinsufficiency unlikely
• Strength of Evidence (disclaimer): Haploinsufficiency unlikely

Evidence for haploinsufficiency phenotype

PubMed ID	Description
32487729	Rausell et al. (2020) suggested that this gene is dosage sensitivity unlikely because it had at least one homozygous LoF variant present in >1% of the gnomAD population. Examples of homozygous LoF variants in this gene in gnomAD include p.Ser201Ter (1 homozygous individual), p.Ala192LeufsTer8 (403 homozygous individuals), and p.Trp150Ter (1 homozygous individual).
22344438	MacArthur et al. (2012) suggested that this gene is dosage sensitivity unlikely because it had at least one homozygous LoF variant present at >5% of the 1000 Genomes Project database.
26940866	Narasimhan et al. (2016) identified rare homozygous loss-of-function (rnLOF) variants in a British Pakistani population characterized as healthy, pregnant, or type 2 diabetic. The variants were compared with an Icelandic population and the ExAC database and a HSD17B13 variant was found in the British Pakistani and ExAC populations.
32461654	Karczewski et al. (2020) identifies 443,769 high confidence loss of function variants in the Genome Aggregation Database (gnomAD) population including these variants (p.Ser201Ter, p.Ala192LeufsTer8, and p.Trp150Ter). Several methods were used to identify these genes including manual curation and utilizing LOEUF scores.

Haploinsufficiency phenotype comments:

This gene was classified as dosage sensitivity unlikely on 2/2/2021 based on review of population data as described in the PMIDs above. These genes all have at least one curated homozygous loss of function variant in 1% or greater of the gnomAD population dataset and some have also been observed in additional population datasets. As of January 2021, there are no disease associations found in OMIM, and no reports suggesting a Mendelian disease association in the literature. The gnomAD pLI score is 0 and the LOEUF score is 1.14 predicting that this gene is tolerant of LoF variation.

• Triplosensitivity score: 0
• Strength of Evidence (disclaimer): No evidence for dosage pathogenicity